Botanical species · safety record

Comarum palustre

The EFSA Compendium of Botanicals holds 11 constituent measurements and 1 adverse-effect record for Comarum palustre. This page reports what those source records contain and how to reach them. It carries no effect estimate, no dose and no recommendation.

Accepted name in source: Comarum palustre L.

11Constituent measurements
1Safety records
3Cited sources
0Licensed products (Canada)

Regulatory presence

No Health Canada licensed natural health product in the snapshot names this species as a medicinal ingredient under this exact binomial. Absence here means absence from this one register under this one name, not absence from trade, and not a safety verdict.

What the records describe

Constituents measured

  • Epigallocatechin gallate4
  • Agrimoniin3
  • Gallic acid1
  • Gallotannins1
  • Pedunculagin1
  • Proanthocyanidins (condensed tannins)1

Plant parts

  • Aerial part of plants5
  • Flower2
  • Leaves2
  • Roots and other underground parts1
  • Stem1
  • Unspecified1
  • stalk1

Preparations

  • Solvent extraction12

Effect types

  • Digestive1

Target tissues

  • Digestive: pancreas1

Recorded constituents

What analytical work has found in this species, at which plant part and preparation. A measured constituent is a fact about material, not about effect.

SubstancePlant partPreparationConcentrationAnalytical methodSource
AgrimoniinLeavesSolvent extraction121.57 Milligram/gramHigh Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)Resolve DOI
AgrimoniinFlowerSolvent extraction151.54 Milligram/gramHigh Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)Resolve DOI
AgrimoniinAerial part of plantsSolvent extractionHPLC-UVResolve DOI
Epigallocatechin gallateFlowerSolvent extraction0.53 Milligram/gramHigh Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)Resolve DOI
Epigallocatechin gallateLeavesSolvent extraction7.42 Milligram/gramHigh Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)Resolve DOI
Epigallocatechin gallateRoots and other underground partsSolvent extraction3.61 Milligram/gramHigh Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)Resolve DOI
Epigallocatechin gallateStem / stalkSolvent extraction8.16 Milligram/gramHigh Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)Resolve DOI
Gallic acidAerial part of plantsSolvent extractionHPLC-UVResolve DOI
PedunculaginAerial part of plantsSolvent extractionHPLC-UVResolve DOI
Proanthocyanidins (condensed tannins)Aerial part of plantsSolvent extractionHPLC-UVResolve DOI
GallotanninsUnspecifiedSolvent extractionStandard Chromatographic tests (paper- thin layer- and column chromatography)No resolvable identifier

Recorded adverse effects

Adverse effects reported in the source literature, most often in animal or laboratory models at a stated preparation and dose.

EffectTarget tissuePlant partPreparationTest organismTest typeSource
DigestiveDigestive: pancreasAerial part of plantsSolvent extractionIn vitroResolve DOI

Cited sources

The literature the compendium cites for this species. Metatron Health has no relationship with these authors or journals and earns nothing from citing them.

  1. Kashchenko, Nina I., Chirikova, Nadezhda K., Olennikov, Daniil N. Agrimoniin, an Active Ellagitannin from Comarum palustre Herb with Anti-alpha-Glucosidase and Antidiabetic Potential in Streptozotocin-Induced Diabetic Rats . Molecules, 2017, vol. 22, no. 1. DOI
  2. Olennikov, D. N. Ellagitannins and Other Phenolic Compounds from Comarum palustre. Chemistry of natural compounds, 2016, vol. 52, no. 4, p. 721-723. DOI
  3. Naumchik, G. N., Rozentsveig, P. E. Tannins in Comarum palustre. Trudy leningradskogo khimiko-farmatsevticheskogo instituta, 1964, vol. No. 17, p. 202-13.

Boundary

A constituent measurement is a fact about material at a stated preparation, not a statement about what that material does in a person. An adverse-effect or genotoxicity record is an observation reported in a source, most often in an animal or laboratory model. Neither is a Metatron Health conclusion about causality, human risk or benefit, and the absence of a record is not proof that a preparation is safe. Nothing here is diagnosis, prescribing or individual medical care.

Continue